VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

By E. Harrington, D. Bebbington, Jeff Moore, Richele K Rasmussen, Abi O Ajose-Adeogun, T. Nakayama, J. A. Graham, C. Demur, T. Hercend, A. Diu‐Hercend and 3 more. Nature Medicine, 2004

956 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/24b00bd58da228fc9ada7f47116ea404bfe6e09e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

In Molecular Biology

In Oncology

Citations in the corpus

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (2007, background): “In addition to being a potent inhibitor of all three Aurora kinases and FLT3 in the nanomolar range, MK-0457 is also a moderate to strong inhibitor of other kinases, including ABL and JAK2 , which are relevant targets for a range of myeloproliferative disorder”
Targeting polo-like kinase 1 for cancer therapy (2006, background): “The analysis of three novel ATP-competitive Aurora inhibitors — ZM 447439, VX-680 and hesperadin — showed that none of these drugs selectively inhibits only one member of the Aurora family, owing to the close relationship of their kinase domain”
Roles of Aurora Kinases in Mitosis and Tumorigenesis (2007, background): “cancer, and an encouraging effect has been shown (21, 22).”
Mitotic catastrophe: a mechanism for avoiding genomic instability (2011, background): “Great interest into this area has recently been spurred on by the discovery of small chemical inhibitors of AURK family members, including AURKB and AURKA, the latter of which regulates the correct development of multiple mitotic processe”